Posted: 6 November 2025
PureCDM has announced the appointment of Michael Fitzgerald as Director of Biostatistics for the Asia-Pacific region, marking a key milestone in the company’s continued investment in biostatistical leadership and scientific excellence.
With more than 14 years of experience across Australia, Japan, China, and India, Fitzgerald has led and developed biometrics teams supporting global pharmaceutical and biotechnology programmes. His expertise spans clinical trial design and analysis, statistical consulting, SAS programming, and strategic development across a range of therapeutic areas.
PureCDM said the appointment reflects its commitment to expanding regional capability and strengthening scientific and strategic support for clients.
Fitzgerald will work alongside Allan Rosen, Vice President of Biostatistical Consulting (US), to co-lead PureCDM’s global biostatistics function. The pair will oversee an integrated team delivering high-quality statistical consulting and delivery services across regions, ensuring consistency, innovation, and operational excellence.
PureCDM’s expanded biostatistics leadership aims to further support the Asia-Pacific biotech community, helping organisations plan and execute global clinical studies with confidence and scientific rigour.
PureCDM has invited interested partners to connect and learn how PureCDM’s consulting and biostatistics services can help bring studies from bench to submission – and beyond.
